References
- Stevens DA. Coccidioidomycosis. N Engl J Med 1995; 332: 1077–82
- Chiller TM, Galgiani JN, Stevens DA. Coccidioidomycosis. Infect Dis Clin North Am 2003; 17: 41–57
- Ampel NM, Mosley DG, England B, Vertz PD, Komatsu K, Hajjeh RA. Coccidioidomycosis in Arizona: increase in incidence from 1990 to 1995. Clin Infect Dis 1998; 27: 1528–30
- Banuelos AF, Williams PL, Johnson RH, Bibi S, Fredricks DN, Gilroy SA, et al. Central nervous system abscesses due to Coccidioides species. Clin Infect Dis 1996; 22: 240–50
- Rosenstein NE, Emery KW, Werner SB, Kao A, Johnson R, Rogers D, et al. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995–1996. Clin Infect Dis 2001; 32: 708–15
- Nakazawa G, Lulu RE, Koo AH. Intracerebellar coccidioidal granuloma. AJNR Am J Neuroradiol 1983; 4: 1243–4
- Dublin AB, Phillips HE. Computed tomography of disseminated coccidioidomycosis. Radiology 1980; 135: 361–8
- Clemons KV, Sobel RA, Williams PL, Pappagianis D, Stevens DA. Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 2002; 46: 2420–6
- Labadie EL, Hamilton RH. Survival improvement in coccidioidal meningitis by high-dose intrathecal amphotericin B. Arch Intern Med 1986; 146: 2013–8
- Stevens DA, Shatsky SA. Intrathecal amphotericin in the management of coccidioidal meningitis. Semin Respir Infect 2001; 16: 263–9
- Terrell CL. Antifungal agents. Part II. The azoles. Mayo Clin Proc 1999; 74: 78–100
- Graybill JR. Treatment of coccidioidomycosis. Curr Top Med Mycol 1993; 5: 151–79
- Deresinski SC. Coccidioidomycosis: efficacy of new agents and future prospects. Curr Opin Infect Dis 2001; 14: 693–6
- Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263–72
- Kauffman CA. Role of azoles in antifungal therapy. Clin Infect Dis 1996; 22(Suppl 2)S148–153